Saturday 17 October 2026
Export AORT’s income statement to Excel — free account
Artivion, Inc.
AORT Healthcare Medical Devices
Artivion, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $441.3 million, up 13.6% from fiscal 2024. In the quarter to June 2026, revenue grew 11.3%, EPS fell 1,033.3%, free cash flow fell 202.5% and total debt rose 67.5%, each against the same quarter a year earlier. Dividend growth for three consecutive years, revenue growth for five, operating cash flow growth for three.
21.78
0.09
−0.41%
Follow AORT
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
0.00 | 217.19 | 146.48 | 0.00 |
P/S ratio |
4.73 | 4.69 | 3.84 | 2.31 | |
P/FCF ratio |
147.00 | 0.00 | 164.76 | 0.00 | |
P/Operating CF |
89.83 | 105.71 | 1,525.54 | (861.55) | |
P/B ratio |
4.56 | 4.61 | 3.91 | 2.45 | |
Price to Tangible BV |
71.79 | 54.93 | 40.08 | 0.00 | |
EV/Sales |
5.07 | 5.03 | 4.19 | 2.93 | |
EV/EBITDA |
44.00 | 39.51 | 31.66 | 30.52 | |
EV/Operating CF |
70.40 | 55.68 | 33.17 | 33.08 | |
EV/FCF |
157.62 | (726.43) | 179.99 | (105.70) | |
Quick Ratio |
1.99 | 1.66 | 1.74 | 1.76 | |
Current Ratio |
3.93 | 3.53 | 3.86 | 3.47 | |
Net Debt/EBITDA |
7.91 | 9.30 | 13.41 | (178.78) | |
Debt/Assets |
25.39% | 24.62% | 24.73% | 34.16% | |
Debt/Equity |
0.50 | 0.49 | 0.48 | 0.82 | |
Asset Turnover |
0.51 | 0.53 | 0.55 | 0.49 | |
Operating CF/Net income |
3.43 | 8.08 | 0.81 | 0.09 | |
Capex/Depreciation |
(0.81) | (4.78) | (1.26) | (1.59) | |
Interest Coverage |
2.05 | 1.93 | 1.08 | (1.15) | |
Research and Development Expense of Revenue |
7.12% | 7.86% | 7.60% | 7.20% | |
Selling, General and Administrative Expense of Revenue |
50.52% | 49.00% | 52.28% | 63.48% | |
Intangible Assets out of Total Assets |
0.48 | 0.46 | 0.46 | 0.54 | |
Share Based Compensation of Revenue |
5.41% | 3.52% | 7.23% | 6.49% | |
Graham Net Nets |
(0.04) | (0.04) | (0.04) | (0.23) | |
Graham Number |
0.00 | 6.84 | 7.26 | 0.00 | |
Earnings Yield |
(0.54%) | 0.46% | 0.68% | (0.27%) | |
Free Cash Flow Yield |
0.68% | (0.15%) | 0.61% | (1.20%) | |
Revenue per Share |
2.40 | 2.56 | 2.42 | 2.59 | |
Operating CF per Share |
0.47 | 0.43 | 0.02 | (0.03) | |
Capex per Share |
(0.10) | (0.61) | (0.17) | (0.22) | |
Free Cash Flow per Share |
0.37 | (0.18) | (0.14) | (0.25) | |
Cash per Share |
1.55 | 1.43 | 1.16 | 1.59 | |
Shareholders Equity per Share |
9.29 | 9.89 | 9.37 | 9.18 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
9.29 | 9.89 | 9.37 | 9.18 | |
Free Cash Flow |
17.65 | (7.95) | (6.85) | (12.01) | |
Working Capital |
251.66 | 256.53 | 264.82 | 264.45 | |
Capital Expenditures |
(4.61) | (27.51) | (8.00) | (10.75) | |
Net Current Asset Value |
(81.47) | (78.48) | (75.17) | (254.97) | |
EV/EBIT |
83.32 | 65.81 | 51.44 | 66.85 | |
Capex to Sales |
0.04 | 0.24 | 0.07 | 0.09 | |
Price to Operating Income |
77.71 | 61.28 | 47.09 | 52.85 | |
| Other line items | |||||
Average Receivables |
87.67 | 94.79 | 100.69 | 106.01 | |
Average Payables |
13.82 | 17.01 | 15.02 | 20.15 | |
Average Inventory |
87.34 | 86.10 | 89.96 | 95.04 | |
Average Assets |
830.40 | 836.95 | 837.16 | 955.16 | |
Average Common Equity |
371.72 | 362.22 | 372.36 | 432.74 |
Columns are period end dates